Source of report and patient demography:
This spontaneous case was initially received on 08-Dec-2015.
The case report was received from a Health Professional in the United States and concerns a 11 years old male 
patient.
Weight: 72 pounds, Height: 50 inches
Linked Case ID(s): US-BEH-2015056131 (Same patient) and US-BEH-2014046626 (Same patient).
For concomitant medication and therapy dates refer to the appropriate report sections.
Print Time: 15-JUL-2016 02:35 PM If a field is blank, there is no data for that field Page 502 of 517
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
Suspect drug(s), timing and conditions surrounding the onset of reaction(s)/event(s):
The patient received Hizentra (IMMUNOGLOBULIN HUMAN NORMAL) for indication Other selective 
immunoglobulin deficiencies on unknown dates, Batch no: 4349300308, Route of administration: Subcutaneous, 
Dose: 4 g every week.
Additional suspect drug(s):
No additional drugs suspected.
Reaction(s)/event(s) and outcome:
On an unknown date in Nov-2015, the patient experienced stomach infection (serious, outcome: Unknown).
On 07-Dec-2015, the patient experienced Viral infection (non-serious, outcome: Unknown), bacterial infection (non-
serious, outcome: Unknown).
Action taken: Ongoing.
Event treatment: Not reported.
Rechallenge/Dechallenge information: Not applicable.
Reporter's assessment: Not reported.
Company's evaluation and comment:
Seriousness criterion/criteria: Medically significant.
Listedness: According to the Reference Safety Information, the events stomach infection, viral infection and 
bacterial infection are unlisted events of Hizentra.
Case Causality: Unrelated. Patient is prone to infections due to underlying immunodeficiency.